Real-world effectiveness of a topical dihydroavenanthramide D formulation for chronic pruritus: A multicenter clinical study with molecular evidence of pruritogenic pathway modulation
Narra J · 25.06.2026 · 6 (2) · e3116
DOI: 10.52225/narra.v6i2.3116 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Narra J, online erschienen am 25.06.2026. Verfasst von Simone Ribero und 6 weiteren Autor:innen. Beteiligte Einrichtung: Section of Dermatology, Department of Medical Sciences, University of Turin, Turin, Italy. Hauptthemen laut MEDLINE: Pruritus. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Chronic pruritus is a prevalent and clinically burdensome condition that substantially impairs quality of life and is sustained by complex interactions between neuro-immune signaling and epidermal barrier dysfunction. Central mediators implicated in this pruritogenic network include interleukin-4 (IL-4), interleukin-13 (IL-13), interleukin-31 (IL-31), substance P encoded by TAC1, and nerve growth factor (NGF). The aim of this study was to evaluate the real-world effectiveness of a topical formulation containing dihydroavenanthramide D (DHAvD), a neurokinin-1 receptor inhibitor, in combination with barrier-repairing agents for reducing pruritus severity in patients with chronic pruritus of diverse etiologies. A supportive molecular sub-study was also performed to determine whether clinical improvement was accompanied by modulation of cutaneous pruritogenic gene expression. A prospective, single-arm, multicenter clinical study was conducted in 1,000 patients with chronic pruritus of diverse etiologies. The formulation was applied twice daily for 14 days, and pruritus severity was assessed using the 12-Item Pruritus Severity Scale (12-PSS; range 3–22). In a molecular sub-study, 20 patients with chronic idiopathic pruritus underwent paired skin biopsies from symptomatic areas before and after treatment, and cutaneous mRNA expression of IL4, IL13, IL31, TAC1, and NGF was quantified by qRT-PCR. The mean 12-PSS score decreased from 11.37±3.71 at baseline to 5.64±2.87 at day 14 (d=−1.72; p
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Section of Dermatology, Department of Medical Sciences, University of Turin, Turin, Italy.
- Section of Dermatology, Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy.
- Private Practice, Marsala, Italy.
- Private Practice, Bassano del Grappa, Italy.
- Private Practice, Brescia, Italy.
- Studio Minoretti, Oggiono, Lecco, Italy.
Zitieren
APA
Ribero, S., Vaccaro, M., Borgia, F., Mattozzi, C., Zattra, E., Mattiucci, A., & Minoretti, P. (2026). Real-world effectiveness of a topical dihydroavenanthramide D formulation for chronic pruritus: A multicenter clinical study with molecular evidence of pruritogenic pathway modulation. Narra J, 6(2), e3116. https://doi.org/10.52225/narra.v6i2.3116
Vancouver
Ribero S, Vaccaro M, Borgia F, Mattozzi C, Zattra E, Mattiucci A, et al. Real-world effectiveness of a topical dihydroavenanthramide D formulation for chronic pruritus: A multicenter clinical study with molecular evidence of pruritogenic pathway modulation. Narra J. 2026;6(2):e3116. doi:10.52225/narra.v6i2.3116
BibTeX
@article{Ribero2026,
author = {Ribero, Simone and Vaccaro, Mario and Borgia, Francesco and Mattozzi, Carlo and Zattra, Edoardo and Mattiucci, Alessandra and Minoretti, Piercarlo},
title = {Real-world effectiveness of a topical dihydroavenanthramide D formulation for chronic pruritus: A multicenter clinical study with molecular evidence of pruritogenic pathway modulation},
journal = {Narra J},
year = {2026},
volume = {6},
number = {2},
pages = {e3116},
doi = {10.52225/narra.v6i2.3116}
}
EUVIMED